Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 17Lung Neoplasms 5Myelodysplastic Syndromes 4Prostatic Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Myeloid, Acute 3Leukemia 3Urinary Bladder Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Primary Myelofibrosis 2Lymphoma, Large B-Cell, Diffuse 2Hematologic Neoplasms 2Glioblastoma 2Breast Neoplasms 2Tumor Virus Infections 1Thyroid Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Recurrence 1Peritoneal Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Plasma Cell 1

Interventions

Carboplatin 4130-nm albumin-bound paclitaxel 4Oxaliplatin 3Leucovorin 3Gemcitabine 3Fluorouracil 3Cisplatin 3Albumin-Bound Paclitaxel 3pembrolizumab 2Pemetrexed 2Paclitaxel 2Cetuximab 2Bevacizumab 2tremelimumab 1durvalumab 1cc-486 1amatuximab 1EC regimen 1CP protocol 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Pancreatic Ductal × Azacitidine × Thoracic × Clear all
NCT01478685 2019-11-12

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Celgene

Phase 1 Completed
169 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence, Tumor Virus Infections, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡